Høhloch, Karin

[["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Lakhani, Vijai J."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Jung, Werner"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T11:14:10Z"],["dc.date.available","2018-11-07T11:14:10Z"],["dc.date.issued","2008"],["dc.format.extent","184"],["dc.identifier.isi","000256693500359"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54064"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","10th International Conference on Malignant Lymphoma"],["dc.relation.eventlocation","Lugano, SWITZERLAND"],["dc.relation.issn","0923-7534"],["dc.title","Tandem HD-chemotherapy and myeloablative radioimmunotherapy with 131I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma: Final results of a phase II study of the German Rait Study Group"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","236"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","British Journal of Haematology"],["dc.bibliographiccitation.lastpage","245"],["dc.bibliographiccitation.volume","180"],["dc.contributor.author","Hohloch, K."],["dc.contributor.author","Altmann, B."],["dc.contributor.author","Pfreundschuh, M."],["dc.contributor.author","Loeffler, M."],["dc.contributor.author","Schmitz, N."],["dc.contributor.author","Zettl, F."],["dc.contributor.author","Ziepert, M."],["dc.contributor.author","Trümper, L."],["dc.date.accessioned","2021-06-01T10:47:11Z"],["dc.date.available","2021-06-01T10:47:11Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1111/bjh.15029"],["dc.identifier.issn","0007-1048"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85514"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","0007-1048"],["dc.title","Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2225"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Leukemia"],["dc.bibliographiccitation.lastpage","2229"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Fürstenau, Moritz"],["dc.contributor.author","Langerbeins, Petra"],["dc.contributor.author","De Silva, Nisha"],["dc.contributor.author","Fink, Anna Maria"],["dc.contributor.author","Robrecht, Sandra"],["dc.contributor.author","von Tresckow, Julia"],["dc.contributor.author","Simon, Florian"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Droogendijk, Jolanda"],["dc.contributor.author","van der Klift, Marjolein"],["dc.contributor.author","van der Spek, Ellen"],["dc.contributor.author","Illmer, Thomas"],["dc.contributor.author","Schöttker, Björn"],["dc.contributor.author","Fischer, Kirsten"],["dc.contributor.author","Wendtner, Clemens M."],["dc.contributor.author","Tausch, Eugen"],["dc.contributor.author","Stilgenbauer, Stephan"],["dc.contributor.author","Niemann, Carsten U."],["dc.contributor.author","Gregor, Michael"],["dc.contributor.author","Kater, Arnon P."],["dc.contributor.author","Hallek, Michael"],["dc.contributor.author","Eichhorst, Barbara"],["dc.date.accessioned","2021-04-14T08:25:50Z"],["dc.date.available","2021-04-14T08:25:50Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1038/s41375-020-0941-7"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81744"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1476-5551"],["dc.relation.issn","0887-6924"],["dc.title","COVID-19 among fit patients with CLL treated with venetoclax-based combinations"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1307"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1315"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Sahlmann, Carsten Oliver"],["dc.contributor.author","Lakhani, Vijai J."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T08:50:15Z"],["dc.date.available","2018-11-07T08:50:15Z"],["dc.date.issued","2011"],["dc.description.abstract","A phase II trial evaluated safety, feasibility and efficacy of a sequential tandem approach combining myeloablative BEAM chemotherapy and autologous stem cell transplantation (ASCT) with myeloablative radioimmunotherapy (HD-RIT), with I-131-anti-CD20 antibody (I-131-rituximab), followed by a second ASCT in patients with relapsed or refractory CD20+ B-cell lymphoma. According to protocol, 16 patients with relapsed (n=14) and refractory (n=2) CD20+ B-cell lymphoma received salvage therapy with rituximab and Dexa-BEAM, followed by BEAM (HD chemotherapy) and high-dose myeloablative radioimmunotherapy 2-6 months after BEAM. Nine of 16 patients received HD-RIT; seven patients were excluded before HD-RIT because of toxicity or progressive disease. Disease histologies were follicular lymphoma (FL) grades 1 and 2 (n=4), transformed follicular (FL 3b; n=6), diffuse large B-cell (DLBCL; n=4), mantle cell (n=1) and marginal zone lymphoma (n=1). After a median follow-up of 50.4 months for OS and 39.7 months for progression-free survival (PFS), estimated 4-year OS and PFS were 67% and 64%, respectively. The estimated 4-year OS and PFS for patients with FL were 80% and 78%, respectively. Toxicity was significant, including one fatal outcome due to pneumonitis. Tandem transplants consisting of HD chemotherapy followed by HD-RIT with I-131-coupled anti-CD20 are manageable and effective but toxic treatment modalities for relapsed poor prognosis CD20+ B-NHL."],["dc.identifier.doi","10.1007/s00277-011-1199-y"],["dc.identifier.isi","000296730300008"],["dc.identifier.pmid","21360108"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7836"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21653"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with I-131-anti-CD20 antibody and stem cell rescue"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1031"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1038"],["dc.bibliographiccitation.volume","100"],["dc.contributor.author","Zettl, Florian"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Altmann, Bettina"],["dc.contributor.author","Zeynalova, Samira"],["dc.contributor.author","Held, Gerhard"],["dc.contributor.author","Pöschel, Viola"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Wulf, Gerald G."],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Trümper, Lorenz"],["dc.date.accessioned","2021-04-14T08:30:49Z"],["dc.date.available","2021-04-14T08:30:49Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00277-020-04345-3"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83385"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","496"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Der Onkologe"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Zettl, Florian"],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T09:56:43Z"],["dc.date.available","2018-11-07T09:56:43Z"],["dc.date.issued","2015"],["dc.description.abstract","Aggressive lymphomas are more frequent in elderly patients and the median age at diagnosis is 64 years. Rational treatment decisions for elderly patients are difficult to make and often influenced by other factors, such as comorbidities and social status as well as experience and preferences of treating physicians. The results of published studies are summarized and discussed in this article. Recommendation for decision-making in this patient collective are presented. This article is based on a PubMed search using the terms aggressive lymphoma, elderly and therapy and on the evaluation of data from the German high-grade non-Hodgkin lymphoma study group. Even in elderly patients with aggressive lymphomas a combined immunochemotherapy including anthracyclines is the only curative treatment approach with a 5-year overall survival of approximately 75 % in fit elderly patients. The decision on whether such a regimen is feasible or a palliative life-extending concept should be selected, can only be made after a prephase therapy for individual patients. In addition, comorbidities and social factors, such as limitations in daily life activities must be incorporated into the treatment plan in this patient population. Geriatric assessments may aid the establishment of rational approaches. The final decision has to be made by the treating physician in close interaction with the patient and relatives."],["dc.identifier.doi","10.1007/s00761-014-2830-z"],["dc.identifier.isi","000355251500006"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37019"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1433-0415"],["dc.relation.issn","0947-8965"],["dc.title","Aggressive B cell lymphomas in elderly patients. Curative or palliative treatment strategy?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","949"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","British Journal of Haematology"],["dc.bibliographiccitation.lastpage","956"],["dc.bibliographiccitation.volume","184"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Windemuth-Kieselbach, Christiane"],["dc.contributor.author","Kolz, Julia"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Cacchione, Roberto"],["dc.contributor.author","Jurczak, Woijciech"],["dc.contributor.author","Bischof Delaloye, Angelika"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Scholz, Christian W."],["dc.date.accessioned","2021-06-01T10:47:12Z"],["dc.date.available","2021-06-01T10:47:12Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1111/bjh.15712"],["dc.identifier.issn","0007-1048"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85516"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","0007-1048"],["dc.title","Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Jung, Werner"],["dc.contributor.author","Stitz, E."],["dc.contributor.author","Meller, J."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T10:18:39Z"],["dc.date.available","2018-11-07T10:18:39Z"],["dc.date.issued","2005"],["dc.format.extent","135"],["dc.identifier.isi","000233670100335"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41490"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","9th International Conference on Malignant Lymphoma"],["dc.relation.eventlocation","Lugano, SWITZERLAND"],["dc.relation.issn","0923-7534"],["dc.title","Tandem high dose chemotherapy and myeloablative radioimmunotherapy with 131-I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma: Interim results of a phase II study of the German RIT study group"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3994"],["dc.bibliographiccitation.issue","24"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","4001"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Stilgenbauer, Stephan"],["dc.contributor.author","Zenz, Thorsten"],["dc.contributor.author","Winkler, Dirk"],["dc.contributor.author","Buehler, Andreas"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Groner, Silja"],["dc.contributor.author","Busch, Raymonde"],["dc.contributor.author","Hensel, Manfred"],["dc.contributor.author","Duehrsen, Ulrich"],["dc.contributor.author","Finke, Juergen"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Jaeger, Ulrich"],["dc.contributor.author","Lengfelder, Eva"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Soeling, Ulrike"],["dc.contributor.author","Schlag, Rudolf"],["dc.contributor.author","Kneba, Michael"],["dc.contributor.author","Hallek, Michael"],["dc.contributor.author","Doehner, Hartmut"],["dc.date.accessioned","2018-11-07T11:25:39Z"],["dc.date.available","2018-11-07T11:25:39Z"],["dc.date.issued","2009"],["dc.description.abstract","Purpose The phase II CLL2H trial evaluated safety and efficacy of subcutaneous alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). Clinical and biologic markers were evaluated for their impacts on outcome. Patients and Methods One hundred nine patients were enrolled, and 103 received at least one dose of alemtuzumab. After dose escalation, alemtuzumab was administered subcutaneously at 30 mg three times weekly for up to 12 weeks. Response was assessed every 4 weeks during treatment and quarterly thereafter. Results The overall response rate was 34% (complete response, 4%; partial response, 30%). The median progression-free survival was 7.7 months, and the median overall survival ( OS) was 19.1 months. Grades 3 to 4 neutropenia, thrombocytopenia, and anemia occurred in 56%, 57%, and 49% of patients, respectively. Grades 3 to 4 noncytomegalovirus and cytomegalovirus infections occurred in 29% and 8% of patients, respectively. Injection-site skin reactions were generally mild. Efficacy did not vary significantly in subgroups defined by genetic parameters ( in particular, in 17p deletion, 11q deletion, mutated TP53, and unmutated VH), but efficacy was inferior in patients with increased beta 2-microglobulin (beta 2-MG) and thymidine kinase (TK). In multivariate analysis of clinical and biologic variables, age, performance status, beta 2-MG, and TK were independent prognostic factors for OS. Conclusion Subcutaneous alemtuzumab appears as effective and safe as intravenous alemtuzumab in fludarabine-refractory CLL. Subcutaneous administration should be the preferred delivery route because of its efficacy, convenience, improved adverse effect profile, and cost savings. In contrast to chemotherapy-based therapy, alemtuzumab treatment overcomes the adverse prognostic impact of VH mutation status, TP53 mutation, and genomic aberrations."],["dc.identifier.doi","10.1200/JCO.2008.21.1128"],["dc.identifier.isi","000269064300021"],["dc.identifier.pmid","19597025"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56671"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","50th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","0732-183X"],["dc.title","Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1585"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.lastpage","1592"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Lankeit, Henrike Katharina"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Scholz, C. W."],["dc.contributor.author","Lorsbach, Michael"],["dc.contributor.author","Windemuth-Kieselbach, C."],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T09:37:21Z"],["dc.date.available","2018-11-07T09:37:21Z"],["dc.date.issued","2014"],["dc.description.abstract","Purpose Very few reliable clinical data about the use of radioimmunotherapy in aggressive B-cell lymphoma exist. Methods Patients with aggressive B-cell lymphoma registered in the international RIT-Network were analysed with regard to prior treatment, response and side effects. The RIT-Network is a web-based registry that collects observational data from radioimmunotherapy-treated patients with malignant lymphoma across 13 countries. Results This analysis included 215 with aggressive B-cell lymphoma out of 232 patients registered in the RIT-Network. Histological subtypes were as follows: 190 diffuse large B-cell, 15 primary mediastinal, 9 anaplastic large cell, and 1 intravascular lymphoma. The median age of the patients was 62 years (range 17 - 88), with 27 % above the age of 70 years. Radioimmunotherapy was mainly used as consolidation after first-line or second-line chemotherapy (56.1 %), as part of third-line to eighth-line therapy for relapse (16.4 %), and in refractory disease (12.2 %). Grade IV neutropenia and thrombopenia and grade III anaemia were observed. The median time to recovery of blood count was 81 days (range 0 - 600 days). The overall response rate was 63.3 %. The complete response rate was 76.4 % in patients treated as part of first-line therapy, and 44.3 % in patients with relapse. Mean overall survival in first-line therapy patients was 32.7 months and 14.0 months in patients with relapse or refractory disease, respectively. Conclusion Most patients with aggressive B-cell lymphoma in the RIT-Network received radioimmunotherapy as consolidation after first-line therapy with excellent complete remission and overall survival rates compared to published data. In relapsed aggressive B-cell lymphoma, radioimmunotherapy is a safe and feasible treatment leading to satisfactory response rates with acceptable toxicity."],["dc.description.sponsorship","Bayer Healthcare"],["dc.identifier.doi","10.1007/s00259-014-2758-y"],["dc.identifier.isi","000339334000014"],["dc.identifier.pmid","24722703"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32822"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1619-7089"],["dc.relation.issn","1619-7070"],["dc.title","Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]